ACCR Stock Overview
A medical marijuana clone company, manufactures and distributes medical marijuana clone products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Access-Power & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.002 |
| 52 Week High | US$0.0039 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 11 Month Change | 42.86% |
| 3 Month Change | 42.86% |
| 1 Year Change | 25.00% |
| 33 Year Change | -85.61% |
| 5 Year Change | 233.33% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACCR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 185.7% | -1.3% | -2.8% |
| 1Y | 25.0% | 18.3% | 16.6% |
Return vs Industry: ACCR exceeded the US Pharmaceuticals industry which returned 18.3% over the past year.
Return vs Market: ACCR exceeded the US Market which returned 16.6% over the past year.
Price Volatility
| ACCR volatility | |
|---|---|
| ACCR Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACCR's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ACCR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Stephane Bontemps | www.myaccess-power.com |
Access-Power & Co., Inc., a medical marijuana clone company, manufactures and distributes medical marijuana clone products. It offers marijuana clone products under the Clones By Drones and Clones by Cars names; and calming pet products through mycbdpets.com. The company was founded in 1996 and is based in Grand Haven, Michigan.
Access-Power & Co., Inc. Fundamentals Summary
| ACCR fundamental statistics | |
|---|---|
| Market cap | US$903.00k |
| Earnings (TTM) | US$3.86k |
| Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs ACCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$3.86k |
| Earnings | US$3.86k |
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ACCR perform over the long term?
See historical performance and comparison